Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scar gel aims to outperform current treatments in 90-Day trial

NCT ID NCT06751433

Symptom relief Sponsor: Herbarium Laboratorio Botanico Ltda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a scar gel against a leading product to see which better prevents raised scars and improves scar appearance, hydration, and color. Eighty adults with recent scars (from C-sections, breast implants, or cuts) will use the gel daily for 90 days. Doctors and participants will rate the results using standard scales and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
scar gel
What this could lead to
If successful, this could provide a safe and effective option for improving the appearance and feel of new scars.
What could go wrong
This is an early-phase study with only 80 participants, so results may not apply to everyone. The gel may not work better than existing products.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants of both sexes aged between 18 and 70 years; 2. Participants with recent scars (\<30 days); 3. Participants with phototypes III to VI according to the Fitzpatrick scale; 4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations; 5. Understand, agree to and sign the free and informed consent form. 6. Types of scars: cesarean section, breast implant or blunt cut injury. Exclusion Criteria: 1. Pregnancy or risk of pregnancy; 2. History of atopic or allergic reactions to cosmetic products; 3. Participants who are using topical antibiotics or other skin products on the same area being evaluated; 4. Immunosuppression due to drugs or active diseases; 5. Decompensated endocrine diseases; 6. Relevant clinical history or current evidence of alcohol or other drug abuse; 7. Known history or suspected intolerance to products in the same category; 8. Intense sun exposure up to 15 days before the evaluation; 9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acceptability study are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cicatrix, Hypertrophic keloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acceptability study Hypertrophic scars Keloid scars Real-use conditions Safety and efficacy Topical administration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MEDCIN

    RECRUITING

    Osasco, Brazil

  • Medcin Instituto da Pele Ltda

    NOT_YET_RECRUITING

    Osasco, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.